Ticker Details
ACADIA Pharmaceuticals Inc. ACADIA Pharmaceuticals Inc is a biotechnology company which develops and commercializes biopharmaceutical products to address central nervous system disorders. It aims to discover small molecule drugs to address Parkinson's, Alzheimer's and schizophrenia.
IPO Date:	June 1, 2004
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$3.61B
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.44 | 2.66%
Avg Daily Range (30 D):	$0.35 | 1.61%
Avg Daily Range (90 D):	$0.43 | 1.86%

Institutional Daily Volume
Avg Daily Volume:	1.22M
Avg Daily Volume (30 D):	1.32M
Avg Daily Volume (90 D):	1.33M

Trade Size
Avg Trade Size (Sh.):	126
Avg Trade Size (Sh.) (30 D):	59
Avg Trade Size (Sh.) (90 D):	60

Institutional Trades
Total Institutional Trades:	10,352
Avg Institutional Trade:	$2.35M
Avg Institutional Trade (30 D):	$4.46M
Avg Institutional Trade (90 D):	$4.1M
Avg Institutional Trade Volume:	.1M
Avg Institutional Trades (Per Day):	3

Market Closing Trades
Avg Closing Trade:	$4.31M
Avg Closing Trade (30 D):	$8.24M
Avg Closing Trade (90 D):	$7.37M
Avg Closing Volume:	179.57K

News

Dec 4, 2025 @ 12:12 AM Acadia Stock Up 59% in a Year — Is a $51 Mi... Source: Jonathan Ponciano

Sep 11, 2025 @ 3:30 AM Questex’s Fierce Pharma Announces the 2025 ... Source: Linda Lam

Apr 22, 2025 @ 5:00 PM Parkinson’s Disease Therapeutic Domain Proj... Source: Delveinsight

Feb 11, 2025 @ 8:48 AM Neuroregeneration Therapy Market to Surpass USD 64... Source: Transparency Market Research

Jun 27, 2024 @ 12:41 PM This Vertex Pharmaceuticals Analyst Begins Coverag... Source: Avi Kapoor

Financials
	TTM	Q1 2026	Q4 2025
Basic EPS	$2.23	$.02	$1.62
Diluted EPS	$2.21	$.02	$1.61
Revenue	$1.1B	$268.06M	$283.99M
Gross Profit	$1B	$243.27M	$257.76M
Net Income / Loss	$375.65M	$3.64M	$273.57M
Operating Income / Loss	$80.91M	$-4.62M	$17.39M
Cost of Revenue	$93.4M	$24.79M	$26.23M
Net Cash Flow	$63.54M	$104.49M	$-81.93M
PE Ratio